Investigational Drug Information for Combretastatin
✉ Email this page to a colleague
What is the development status for investigational drug Combretastatin?
Combretastatin is an investigational drug.
There have been 19 clinical trials for Combretastatin.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2015.
The most common disease conditions in clinical trials are Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic, and Thyroid Diseases. The leading clinical trial sponsors are Mateon Therapeutics, National Cancer Institute (NCI), and Case Comprehensive Cancer Center.
There are nine hundred and ninety-four US patents protecting this investigational drug and eleven international patents.
Summary for Combretastatin
| US Patents | 994 |
| International Patents | 11,960 |
| US Patent Applications | 6,471 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 1,200 |
| Clinical Trial Progress | Phase 2 (2015-03-01) |
| Vendors | 8 |
Recent Clinical Trials for Combretastatin
| Title | Sponsor | Phase |
|---|---|---|
| FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer | Mateon Therapeutics | Phase 2/Phase 3 |
| Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS | Mateon Therapeutics | Phase 1/Phase 2 |
| Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer | Mateon Therapeutics | Phase 3 |
Clinical Trial Summary for Combretastatin
Top disease conditions for Combretastatin
Top clinical trial sponsors for Combretastatin
US Patents for Combretastatin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Combretastatin | ⤷ Try a Trial | Method of diagnosing and treating cancer using B-catenin splice variants | The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) | ⤷ Try a Trial |
| Combretastatin | ⤷ Try a Trial | Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers | Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) | ⤷ Try a Trial |
| Combretastatin | ⤷ Try a Trial | Use of inhibitors of Bruton'S tyrosine kinase (Btk) | Pharmacyclics LLC (Sunnyvale, CA) | ⤷ Try a Trial |
| Combretastatin | ⤷ Try a Trial | Use of inhibitors of Bruton's tyrosine kinase (Btk) | Pharmacyclics LLC (Sunnyvale, CA) | ⤷ Try a Trial |
| Combretastatin | ⤷ Try a Trial | Inhibition of hypoxia-inducible factor activity with carica papaya extracts | The Regents of the University of California (Oakland, CA) Universiti Putra Malaysia (Selangor Darul Ehsan, MY) | ⤷ Try a Trial |
| Combretastatin | ⤷ Try a Trial | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor | Pharmacyclics LLC (Sunnyvale, CA) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Combretastatin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Combretastatin | Argentina | AR075939 | 2029-03-25 | ⤷ Try a Trial |
| Combretastatin | Argentina | AR119754 | 2029-03-25 | ⤷ Try a Trial |
| Combretastatin | Australia | AU2010229994 | 2029-03-25 | ⤷ Try a Trial |
| Combretastatin | Brazil | BRPI1006448 | 2029-03-25 | ⤷ Try a Trial |
| Combretastatin | Canada | CA2754163 | 2029-03-25 | ⤷ Try a Trial |
| Combretastatin | China | CN102378767 | 2029-03-25 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
